François Mongrain

Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada.

Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada.